Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb:28:101619.
doi: 10.1016/j.tranon.2023.101619. Epub 2023 Jan 7.

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity

Hui Xing  1 , Yang Wang  2 , Bo Qu  1 , Qiang Wei  2 , Cuihua Li  1 , Chao Pan  1 , Hui Li  3
Affiliations
Review

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity

Hui Xing et al. Transl Oncol. 2023 Feb.

Abstract

ICI-related hepatotoxicity (IRH) is becoming more and more common as immune checkpoint inhibitors (ICIs) have begun to be increasingly approved and used in combination with other anti-tumor drugs worldwide. Steroids are the first choice for the treatment of IRH, but the subsequent optimal treatment algorithm remains unclear if the disease progresses to steroid-refractory IRH. Therefore, in this paper we reviewed all the pertinent literature on steroid-refractory IRH to the greatest extent possible in an attempt to provide information on which to base an update of the treatment algorithm for steroid-refractory IRH.

Keywords: Cholangitis; Drug-resistance; Hepatitis; Hepatotoxicity; Immune checkpoint inhibitors; Steroid.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hui Li reports a relationship with MSD, Abbvie, Pfizer, Takeda, Janssen Pharmaceuticals, Dr. Falk Pharma. that includes: speaking and lecture fees.

Figures

Fig 1
Fig. 1
Potential mechanisms of steroid-refractory IRH. A. Main mechanism of antitumor action of immune cells. B. Brief mechanism of T-cell-mediated hepatotoxicity, and CD3+, CD4+ and CD20+ lymphocytes, neutrophils, and eosinophils were also involved.
Fig 2
Fig. 2
Treatment algorithm for steroid-refractory IRH.
See this image and copyright information in PMC

References

    1. Zou W., Chen L. Inhibitory B7-family molecules in the tumor microenvironment. Nat. Rev. Immunol. 2008;8(6):467–477. doi: 10.1038/nri2326. - DOI - PubMed
    1. Postow M.A., Sidlow R., Hellmann M.D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 2018;378(2):158–168. doi: 10.1056/NEJMra1703481. - DOI - PubMed
    1. Wang W., Lie P., Guo M., He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int. J. Cancer. 2017;141(5):1018–1028. doi: 10.1002/ijc.30678. - DOI - PubMed
    1. Parlati L., Vallet-Pichard A., Batista R., et al. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study. J. Hepatol. 2018;69(6):1396–1397. doi: 10.1016/j.jhep.2018.08.014. - DOI - PubMed
    1. Da L., Teng Y., Wang N., et al. Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials. Front. Pharmacol. 2020;10:1671. doi: 10.3389/fphar.2019.01671. Published 2020 Jan 30. - DOI - PMC - PubMed